Featured Research

from universities, journals, and other organizations

Radiation May Provide A New Ray Of Hope For An Old Problem

Date:
February 2, 2000
Source:
American Heart Association
Summary:
Radiation has long been used as a method for killing cancer cells. Now researchers say radiation looks promising as a way to kill the overgrowth of tissue cells that can lead to a reblockage of a heart artery, according to a report in Circulation: Journal of the American Heart Association.

DALLAS, Feb. 1 -- Radiation has long been used as a method for killing cancer cells. Now researchers say radiation looks promising as a way to kill the overgrowth of tissue cells that can lead to a reblockage of a heart artery, according to a report in today's issue of Circulation: Journal of the American Heart Association.

"Radiation may one day offer a solution to a long-standing problem – reblockage of a heart artery following angioplasty, particularly in patients who receive stents," says lead author Paul S. Teirstein, M.D., director of interventional cardiology at Scripps Clinic in La Jolla, Calif. In angioplasty, a balloon-tipped catheter is threaded into the blocked artery and the balloon is then inflated to widen the narrowed vessel. Sometimes a stent -- a metal coil -- is implanted as well to hold the walls of the vessel open. However, doctors have found that a build-up of scar tissue resulting in a reblockage of the artery is a common complication after a stent is put in.

In this study, a ribbon containing sealed radioactive pellets -- a technique called brachytherapy -- was threaded into the affected artery. The ribbon was left in place for 20 to 45 minutes to administer the prescribed dose of radiation to the artery, and then removed. Researchers report that after three years the patients who received the radiation had less than half the rate of reblockage as patients who did not undergo the radiation treatment.

"Brachytherapy is of particular value to patients with in-stent reblockage for whom there is no effective alternative because their coronary artery disease is so severe," say the authors of an accompanying editorial, David O. Williams, M.D., and Barry L. Sharaf, M.D., division of cardiology at Brown University. Sharaf, an associate professor of medicine at Brown University says the "study alleviates some of the unknowns" about the long-term effectiveness of the radiation treatment. "This is now the largest study with long-term follow-up of this treatment," he says. Although previous studies had found intracoronary radiation to be safe and effective, the scientists involved in this latest study wanted to find out if the procedure was successful over the long-term, and also to make sure there were no long-term adverse health effects associated with it.

"We were concerned that there might be adverse effects that would outweigh the benefits, and that we would be merely delaying the reblockage of these arteries," Teirstein says. "However, this study tells us that after three years, intracoronary radiation continues to be a safe way to treat reblockages of heart arteries."

All the patients in the study had stents, and some had in-stent reblockages. Twenty-six patients received the radiation treatment and 29 did not. Three years later, only 15.4 percent of the patients in the radiation-treated group had reblockages of the affected heart artery, compared to 48.3 percent of the untreated group.

Additionally, researchers found that the rate of deaths, heart attacks and reblockages was much lower in the radiation-treated patients compared to the untreated group (23.1 percent vs. 55.2 percent).

Teirstein says that although the study results are promising, it does not mean that 10 to 20 years out the procedure will show the same effectiveness. "It would be premature to recommend radiation therapy as the first line of treatment for patients with clogged heart arteries," he says, and adds that additional scientific study is needed.

The editorial writers add that further study should be done of specific patient subgroups, including those who receive the radiation implants both with or without stents, and that these patients need to be observed for a longer time period, such as five to 15 years following the procedure.

Co-authors include Vincent Massullo, M.D.; Shirish Jani, Ph.D.; Jeffrey J. Popma, M.D.; Robert J. Russo, M.D., Ph.D.; Richard A. Schatz, M.D.; Erminia M. Guarneri, M.D.; Stephen Steuterman, M.S.; Kathleen Sirkin, R.C.V.T.; David A. Cloutier, B.S.; Martin B. Leon, M.D. and Prabhakar Tripuraneni, M.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Radiation May Provide A New Ray Of Hope For An Old Problem." ScienceDaily. ScienceDaily, 2 February 2000. <www.sciencedaily.com/releases/2000/02/000202080018.htm>.
American Heart Association. (2000, February 2). Radiation May Provide A New Ray Of Hope For An Old Problem. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/02/000202080018.htm
American Heart Association. "Radiation May Provide A New Ray Of Hope For An Old Problem." ScienceDaily. www.sciencedaily.com/releases/2000/02/000202080018.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins